A new Phase 2 clinical trial is shining a spotlight on the potential benefits of Zabopegdutide for MASH patients. HistoIndex’s AI-powered analysis has revealed robust improvements in liver fibrosis, offering a promising glimpse of future treatment possibilities.

Inventiva has made its preparatory documents available for a crucial Combined General Meeting on June 30, 2026. This announcement reflects the company’s commitment to providing timely updates on its clinical-stage biopharmaceutical work focusing on MASH therapy.